Tag:
Synageva BioPharma
Latest Headlines
Latest Headlines
Mitsubishi Tanabe Pharma taps Synageva for orphan disease R&D
Rare disease know-how remains a hot commodity. Aiming to gain access to orphan disease and protein drug-making expertise, Mitsubishi Tanabe Pharma has struck an R&D deal with Synageva BioPharma.
Updated: Synageva goes public in M&A deal with troubled Trimeris
A year after its proposed $81 million acquisition deal with a Korean company fell through, Durham, NC-based Trimeris ( $TRMS ) has struck an all-stock merger pact with Synageva, a Lexington, MA-based
Venture backers inject $25M into Synageva's rare disease platform
Fledgling developer Synageva BioPharma has lined up a fresh injection of $25 million in venture cash to finance its work on rare diseases--a hot field in the biotech world these days. The Lexington,
Calistoga investors return for $30M Series B
Seattle-based Calistoga Pharmaceuticals has kept the faith with its Series A investors, bringing them back for a $30 million second round. Frazier Healthcare Ventures, Alta Partners, Three Arch
Synageva announces $30M round
Waltham, MA-based Synageva BioPharma announced the first closing of its $30 million round of venture financing. The financing was led by Baker Brothers Investments and included Tullis Dickerson and
